Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction

Cerebral Infarction Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Phase I/IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effects After Intravenous Transplantation of Human Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Cerebral Infarction Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02378974
• Other study ID #: CHA-CST-101
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: February 2015
• Est. completion date: April 2017

Study information

• Verified date: November 2019
• Source: CHABiotech CO., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects

Description:

Cohort 1 : Cordstem-ST cells or Placebo on day 0 Cohort 2: Cordstem-ST cells or Placebo on day 0 and day 7

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 80 Years

Eligibility

Inclusion Criteria

1. Male or female subjects between 19 to 80 years of age (inclusive) at the time of screening visit

2. Subjects who are able to receive intravenous Cordstem-ST Transplantation within 7 days (168 hours) of stroke onset

3. Subjects with diagnosis of Cerebral Infarction confirmed by the following criteria assessed at the screening visit

• NIHSS score between 5 and 20 (inclusive)

• Acute ischemic lesion involving anterior circulation territory identified in the diffusion weighted MRI

4. Signed informed consent

Exclusion Criteria

1. History of intracranial hemorrhage

2. Subjects who are suspected to undergo endarterectomy during the study period. Subjects who received the former procedures not due to cerebral infarction more than 3 months ago, are eligible.

3. Subjects with hemorrhagic transformation on brain images, except for petechial hemorrhage ('H1' according to the ECASS classification)

4. Subjects at the high risk of developing brain herniation

5. History of dementia

6. History of epilepsy

7. Subjects who have been treated or diagnosed with schizophrenia, depression, or bipolar disorder within the past 6 months

8. Subjects with recent (=3 months) myocardial infarction or stroke other than the index stroke.

9. Subjects must not have the following conditions in laboratory tests

• ALT or AST: More than 2.5 times the upper limit of normal

• Serum creatinine: More than 1.5 times the upper limit of normal

• Total bilirubin: More than 2.5 times the upper limit of normal

• Platelet count: less than lower limit of narmal

10. Subjects who are HBV, HCV, HIV, VDRL positive

11. Subjects in poor general condition due to medical conditions or subjects with severe cardiovascular, gastrointestinal, pulmonary, endocrinologic diseases

12. Subjects with active lung diseases, based on chest X-ray

13. Subjects with abnormal coagulopathic conditions (thrombocytopenia, congenital coagulopathy, etc.). Medical use of oral anticoagulants is permitted.

14. Subjects with known allergies to protein products (Bovine serum) used in the cell production process.

15. Subjects with history of pulmonary embolism or deep vein thrombosis

16. Subjects with history of malignancy

17. Pregnant or lactating women

18. Women of childbearing age who reject to practice contraception with one of the following methods

• Use a condom

• Use of contraceptive (oral, dermal, or injectable)

• Use an intra-uterine contraceptive device

19. Subjects with a history of alcohol abuse (>30g/day) or drug abuse

20. Subjects who cannot undergo MRI scanning

21. Subjects who cannot conduct the scheduled monitoring visits

22. Subjects who is determined to be inappropriate by the investigators

Related Conditions & MeSH terms

• Cerebral Infarction
• Infarction

Intervention

Biological:
• Cordstem-ST

• Placebo

Locations

Country	Name	City	State
Korea, Republic of	CHA Bundang Medical Center	Seongnam-si	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
CHABiotech CO., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of TEAEs	Number of treatment related-adverse events during the study period	6 month
Secondary	Improvement in clinical function as assessed by mRS	Modified Rankin Score (mRS) compared to baseline at 6 months	6 month
Secondary	Improvement in clinical function as assessed by NIHSS	National Institute of Health Stroke Scale (NIHSS) compared to baseline at 6 months	6 month
Secondary	Improvement in clinical function as assessed by BI	Barthel Index (BI) compared to baseline at 6 months	6 month
Secondary	Improvement in clinical function as assessed by Brain MRI tratogram	Brain MRI tratogram compared to baseline at 6 months	6 month